Research has suggested that ART may increase the risk of pediatric cancers, but studies have shown conflicting results, and questions remain.
Though mortality rates for uterine cancer are on the rise, research for this cancer is underfunded, a study suggests.
About 96% of survey respondents said they preferred to receive test results immediately through the online portal.
PIK3CA and ARID1A may be targets for drug development in recurrent or metastatic cervical cancer, according to researchers.
The conversion from accelerated approval to regular approval was based on data from the KEYNOTE-158 trial, the KEYNOTE-164 trial, and the KEYNOTE-051 trial.
New research suggests that, for patients with ovarian cancer, the risk of VTE increases as patients receive more lines of chemotherapy.
The orphan drug designation for osemitamab is supported by preliminary antitumor activity observed in a phase 1/2a trial.
More than 20% of US patients diagnosed with cancer during pregnancy may be unable to terminate that pregnancy due to abortion laws in their state, a new study suggests.
Adding zolbetuximab to chemotherapy improves survival outcomes in patients with unresectable or metastatic gastric/GEJ cancer, a study suggests.
Patients with advanced or recurrent endometrial cancer spend about 15% of their time addressing health care needs, and this time burden can have a negative effect on their quality of life, a study suggests.
Processed red meat intake is associated with an increased incidence of AML and MDS in a Japanese population, a study suggests.
The environmental impact of prostate MRI and biopsies may be considerable, a study suggests.
Patients with sustained minimal residual disease negativity had longer time to next treatment, regardless of baseline risk characteristics.
Researchers are conducting a phase 3 trial to compare sotorasib plus panitumumab with investigator’s choice of therapy in patients with previously treated, KRAS p.G12C-mutated metastatic colorectal cancer.
Researchers are conducting a phase 3 trial to compare standard care with combination tucatinib, trastuzumab, and chemotherapy as first-line treatment in HER2-positive, unresectable or metastatic colorectal cancer.
Researchers are comparing nivolumab monotherapy, nivolumab plus ipilimumab, and investigator’s choice of chemotherapy in MSI-H/dMMR, recurrent or metastatic colorectal cancer.
Researchers are conducting a phase 3 trial to compare XL092 plus atezolizumab with regorafenib alone in MSS/MSI-low metastatic colorectal cancer.
Patients with advanced ovarian cancer may live longer if they undergo minimally invasive surgery rather than laparotomy, a study suggests.
Niraparib maintenance does not improve overall survival in patients with platinum-sensitive recurrent ovarian cancer, updated data suggest.
Adding dostarlimab to chemotherapy can improve outcomes in patients with primary advanced or recurrent endometrial cancer, a phase 3 trial suggests.
The combination of durvalumab, tremelimumab, and chemotherapy can produce durable responses in patients with newly diagnosed, advanced-stage epithelial ovarian cancer, a phase 2 trial suggests.
Adavosertib is active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma, a phase 2 study suggests.
Adding pembrolizumab to chemotherapy improves progression-free survival in advanced or recurrent endometrial cancer, a phase 3 trial suggests.
Anlotinib enhances the efficacy of pembrolizumab in patients with recurrent or refractory high-grade serous ovarian cancer, a phase 2 study suggests.
Chemoradiotherapy does not improve overall survival, compared with chemotherapy alone, in patients with locally advanced endometrial cancer, a phase 3 trial suggests.
The combination of toripalimab, bevacizumab, and platinum-based chemotherapy appears safe and effective for patients with advanced cervical cancer.
Patients with platinum-resistant epithelial ovarian cancer may have better overall survival if they enroll on a clinical trial than if they receive standard care.
The number of gynecologic oncologists in the US has grown in recent years, but many patients still lack access to a gynecologic oncologist.
Physician reimbursement rates for gynecologic oncology procedures have increased in recent years but have not kept up with inflation, a study suggests.
The combination of gemcitabine, cisplatin, and IMRT appears effective in patients with locally advanced, unresectable vulvar cancer.
Cryocompression can reduce subjective peripheral neuropathy in patients with gynecologic cancer undergoing chemotherapy, a study suggests.
Ribociclib plus letrozole elicits responses in patients with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum, a phase 2 study suggests.
The management of advanced gynecologic cancers remains a challenge, but the treatment landscape is changing.
Researchers found a similarly increased risk of breast cancer for progestogen-only contraceptives and oral combined contraceptives.
Molecular testing may be underused in patients with metastatic NSCLC and may delay the start of systemic therapy, a study suggests.
Drug shortages in the United States increased nearly 30% between 2021 and 2022, according to a Senate report.
The FDA has granted accelerated approval to Zynyz (retifanlimab) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Mammography use is still higher among White patients than among American Indian patients, but the gap is narrowing due to declining mammography use in White patients.
Antibiotics may prevent bacteria-mediated chemoresistance in patients with metastatic pancreatic cancer, a new study suggests.
Patients with solid tumors do not appear to have an increased risk of side effects from COVID-19 vaccination, according to a systematic review.
Adding ipilimumab to nivolumab and chemotherapy improves responses in patients with operable non-small cell lung cancer, a phase 2 trial suggests.
Military pilots and the ground crews who fuel and maintain their aircraft have higher rates of certain cancers, a new study shows.
Merck has decided to end the phase 3 KEYNOTE-991 trial due to futility.
Ulenistamab targets PAUF, a tumor-specific protein that is overexpressed in pancreatic cancer cells.
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Surgical resection generally improves long-term outcomes over local resection in high-risk, T1 colorectal cancer, a study suggests.
Patients receiving higher doses of hormone therapy and those receiving hormone therapy for at least 5 years may have a lower risk of lung cancer.
Among African-American cancer survivors, experiencing discrimination is associated with frailty, a study suggests.
Oral nicotinamide does not reduce the risk of keratinocyte cancers in organ transplant recipients, a study suggests.
Authors present a concise overview of the diagnosis, risk factors, and treatment of basal cell carcinoma.
Low-dose tamoxifen reduces the risk of breast cancer among patients with intraepithelial neoplasia for several years, data suggest.
The prevalence of hand-foot syndrome after chemotherapy is high among patients with colorectal cancer, according to researchers.
New findings could have implications for the use of salvage therapies.
Findings may inform treatment decisions after nephrectomy with positive surgical margins.
About 15% of nonelderly US adults surveyed said they or their families have past-due medical debt.
Several factors influenced the likelihood of COVID-19 vaccination among patients with cancer who already had COVID-19, a new study suggests.
Adding vistusertib to treatment with paclitaxel does not improve outcomes in patients with platinum-resistant or -refractory ovarian cancer, a phase 2 trial suggests.
The median survival for patients with metastatic bladder cancer is increasing, possibly due to increasing use of immunotherapy.
Postoperative adverse events can delay chemotherapy but do not affect survival outcomes in patients with platinum-sensitive, recurrent ovarian cancer, a study suggests.
The FDA approved the combination to treat pediatric patients 1 year of age and older who have low-grade glioma with a BRAF V600E mutation and require systemic therapy.
A proposed regulation would require US public water systems to reduce the level of PFAS in drinking water.
Researchers are conducting a phase 2 trial to test pembrolizumab and tamoxifen, with or without vorinostat, in patients with ER+ breast cancer.
Researchers are testing valemetostat plus trastuzumab deruxtecan in patients with HER2-low/ultra-low/null metastatic breast cancer.
Researchers are conducting a phase 1b/2 trial to test tucatinib plus alpelisib in patients with advanced,
PIK3CA-mutant, HER2+ breast cancer.
Researchers are conducting a phase 1 trial to test CAR T-cell therapy in patients with mesothelin-expressing triple-negative breast cancer.
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief.
Non-frail patients with early-stage breast cancer have an increased risk of worsening frailty status after locoregional therapy, a study suggests.
Investigators analyzed data from 3 randomized controlled trials and data from their own prospective institutional database.
A majority of physicians surveyed said that prior authorization results in increased use of health care resources, and one-third said prior authorization led to a serious adverse event for a patient.
Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
The FDA has authorized use of the bivalent Pfizer-BioNTech COVID-19 vaccine as a booster dose for children 6 months through 4 years of age.
Among older patients with diabetes, metformin was associated with a reduced risk of cancer, but the combination of aspirin and metformin was associated with an increased risk of cancer death.
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
The mean time to resolution of axillary lymphadenopathy after a COVID-19 vaccine booster is 102 days, according to a study.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Patients undergoing radical cystectomy for bladder cancer have an increased risk of thromboembolic events that may persist for months after surgery.
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Personalized ctDNA monitoring can predict outcomes during and after treatment in patients with advanced melanoma, a study suggests.
Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.
Adding ramucirumab to first-line chemotherapy does not improve outcomes in patients with advanced pancreatic ductal adenocarcinoma, a study suggests.
New research suggests that men with localized prostate cancer have low prostate cancer-specific mortality at 15 years, regardless of the treatment they receive.
Lenvatinib plus pembrolizumab improved outcomes vs sunitinib in patients with advanced renal cell carcinoma.
Fifty US organizations have launched the Coalition for Trust in Health & Science to curb health and science misinformation and disinformation.
Updated results support the use of adjuvant paclitaxel and trastuzumab in small, node-negative, HER2-positive breast cancer, according to researchers.
The risk of hyperprogression is lower when atezolizumab is given upfront to patients with advanced non-small cell lung cancer, a study suggests.
Pembrolizumab can produce responses in patients with diffuse malignant peritoneal mesothelioma, according to a retrospective study.
Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
Aortic calcification may lead to arterial degradation that increases the risk for acute kidney injury, according to investigators.
An FDA panel voted in favor of approving polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL.
A multipronged initiative increased germline BRCA mutation testing for patients with ovarian cancer by 31%.
Alisertib monotherapy has shown activity in postmenopausal patients with endocrine-resistant, HER2-negative, metastatic breast cancer, but it was not able to restore sensitivity to fulvestrant in this patient population.
Compared with standard care, preoperative short-course RT followed by chemotherapy can decrease distant metastasis in patients with high-risk LARC.
A larger proportion of patients with private or Medicare insurance received a diagnosis of early-stage cervical cancer.
Pluvicto is currently in shortage due to challenges in meeting demand and no therapeutic equivalents being available.
Nearly 75% of poll respondents who needed health care in the past 6 months experienced delays or challenges in getting that care.
Studies suggest that ctDNA testing has prognostic value in colorectal cancer, but more research is needed before it can be used in practice.
A phase 2 trial suggests that frontline osimertinib and platinum-based chemotherapy is safe and effective in EGFR-mutated, advanced NSCLC.